Lifescience Dynamics Limited published an article in Pharmaceutical Executive exploring changes in competitive intelligence after twenty-two years in the industry.
Public source
Publisher name
Public post
Pharma Has More Data Than Ever, This Doesn’t Mean It Has Better Intelligence. Pharmaceutical companies have never had access to more information about their competitors.…
Company
Lifescience Dynamics Limited
A decision support consultancy helping clients manage complex strategic issues
- Industry
- Business Consulting and Services
- Location
- London, GB
- Company size
- 51–200 employees
About Lifescience Dynamics Limited
Winner of the prestigious King's Award for Enterprise 2023, Queen's Award for Enterprise 2016 and ranking in Vault.com’s 25 Best Consulting Companies to work for - Lifescience Dynamics is a decision support firm providing the world's top 25 largest life sciences companies (pharmaceutical, biotechnology, diagnostics and medical devices) with strategic insight and foresight to improve their assumptions, enabling them to make better decisions. Lifescience Dynamics works across five practice areas: Market Research, Competitive Intelligence, and Market Access and Strategic Advisory. The company’s success is attributed to its multinational team who work in a collaborative and nurturing environment, where they can develop their skills and advance their careers. Founded in 2004, Lifescience Dynamics has its headquarters in London and an office in Toronto, as well as virtual offices in Vancouver, Boston, New York, San Francisco and Krakow.
See moreLatest activity
Latest activity from Lifescience Dynamics Limited
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Prescient
Prescient released the Disease Area Strategy Impact Index to provide senior pharma leaders with an independent perspective to strengthen strategy, improve decision making, and identify opportunities to deliver industry best practice across their portfolio.
Research & Knowledge
London Strategy
London Strategy published an article by Aparna Kapse on how FDA approval timelines and EMA credibility are shaping deal value, structure, and sequencing in pharma M&A in 2026.
Research & Knowledge
DLRC Regulatory Consultancy
DLRC Regulatory Consultancy published an article exploring the implications of the proposed EU Pharmaceutical Reform for industry and how ePI may transform medicines information creation, management, and access.
Research & Knowledge
Indegene
Indegene published a new report by Devashish Satarkar, Mohd. Fakhrul I. Khan, and Saurav Patani exploring how pharma teams can turn congress signals into a continuous intelligence capability.
Research & Knowledge
PQE Group